Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Research Abstract |
The current study was designed to develop the combination methods with dendritic cells and novel chemokine products for preventing the recurrence of hepatocellular carcinoma following the treatments. The methods of dendritic cell induction were modified using OK-432 and zinc, and the chemokine products were evaluated for the activation of the cancer immunity. Furthermore, the biological stability of the products was improved by recombinant technology. Collectively, the results indicated that the modified methods using both dendritic cells and the chemokine products may contribute to the reduction of hepatocellular carcinoma recurrence.
|